Esperion Therapeutics (ESPR) has been under a strong bear grip, hence the stock is down -3.15% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.95% in the past 1 week. The stock has risen by 1.46% in the past week indicating that the buyers are active at lower levels, but the stock is down -3.27% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 0.77% and the 50-Day Moving Average is 4.27%.The 200 Day SMA reached 34.83%. Esperion Therapeutics, Inc. has dropped 41.7% during the last 3-month period . Year-to-Date the stock performance stands at -51.55%.
Esperion Therapeutics (NASDAQ:ESPR): After opening at $10.8, the stock dipped to an intraday low of $10.565 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $10.97 and the buying power remained strong till the end. The stock closed at $10.785 for the day, a gain of 0.23% for the day session. The total traded volume was 218,570. The stocks close on the previous trading day was $10.76.
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Companys primary activities include conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. ETC-1002, the Companys lead product candidate, is an orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.